Evelo Biosciences (EVLO) 10-Q2023 Q1 Quarterly report

Filed: 15 May 23, 4:43pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Good

New words: absence, adding, agent, annum, assimilated, attrition, back, bankruptcy, begun, Bill, bundled, clause, codified, collapse, conceding, constantly, core, counter, delisted, delisting, detachable, diffusion, discourse, Eastern, EVLO, float, forbear, forecast, foreclose, freestanding, Horizon, immunosuppression, inclusion, injected, input, installment, instrument, intrinsic, JAK, Journal, labor, leverage, ministerial, mixture, mobilization, monoclonal, morale, network, nongovernmental, notable, OTCQB, par, PHSA, pledged, potent, preserve, preserved, purified, purported, quotation, reconciliation, regain, reintegrated, relay, resurgence, Roivant, runway, save, sensed, sensing, spanning, SRC, Standstill, stub, symbol, undertaken, undertook, uninsured, unrealized, unwarranted, vesicle, vital, winding, Windsor, workforce

Removed: abdominal, accelerating, accuracy, adjust, adult, Africa, area, AstraZeneca, Balkrishan, Bayesian, began, broader, cardiovascular, carrying, checkpoint, Chicago, circumstance, close, commencing, Commissioner, complement, contact, convert, crystallized, daily, dated, deepening, degeneration, delegated, Dermatology, determining, diarrhea, distancing, dosed, drawn, drew, durability, East, Eczema, embedded, employ, enabling, endeavored, EP, equaling, erythrodermic, extinguishment, feature, flexible, gastrointestinal, gave, geographic, Gilead, Gill, half, harder, IGA, immunological, improved, Index, inform, intention, interactive, introduced, Inventory, investigating, Investigator, issuer, itch, iv, join, left, lien, life, liver, matching, measurable, medium, Merck, metabolic, metabolism, methodology, Middle, migrated, minimize, mission, month, multicenter, nausea, neurobehavior, neurological, Nineteen, notional, objective, oncology, onset, onward, pain, partnership, plc, POEM, point, postpone, prespecified, prioritization, pustular, ramp, ranging, Rating, ratio, reacquisition, recommended, regulator, relied, remote, reply, respiratory, responder, Roche, safest, SCC, serving, shipping, Simba, simultaneously, skin, standalone, suggest, superior, supersede, superseded, supervision, supportable, surface, Symptom, tangible, telecommuting, thirty, tranche, transitional, transport, Trust, Turkey, underlying, University, unpaid, updated, utilized, validated, vest, vivo, vomiting, weighted

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

EVLO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Marella Thorell, Chief Financial Office and Treasurer of Evelo Biosciences, Inc. (the “Company”), hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 (the “Report”) fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 15, 2023

By:

/s/ Marella Thorell

Marella Thorell

Chief Financial Officer and Treasurer

(Principal Financial Officer)